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ABSTRACT Herein, we report that N-alkyl-octahydroisoquinolin-1-one-8-carbox-
amides are a novel class of readily synthesized, selective κ-opioid receptor (KOR)
ligands. A striking feature of this class of compounds is the absence of any basic
nitrogen atoms. Many of these compounds have demonstrated exclusive affinity
for the KORover not only the δ-opioid receptor and the μ-opioid receptor but also
38 other G protein-coupled receptor targets. The general binding affinity of this
class of compounds for the KOR combined with a streamlined route for analogue
synthesis provide strongmotivation for pursuing this interesting new scaffold as a
basis toward new probes targeting the KOR.
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The κ-οpioid receptor (KOR) plays a significant role in abroad range of physiological functions1-3 that include,inter alia, addiction,4,5 depression,6-8 andpain relief.9
Additionally, the naturally occurring hallucinogen salvinorin
A is a potent and selective KOR agonist implicating the KOR
in diseases of human perception.10 Accordingly, there is
great interest in discovering agents that are able to positively
or negativelymodulate KOR function. In addition to a robust
and still-evolving collection of peptide-derived and natural
product ligands that interact with the KOR, synthetic small
molecules are of particular interest as potential therapeutic
compounds.11-13 Three notable recent examples of the
latter are the aryl acetamide class of KOR agonists, exem-
plified by U-50,488,14 first introduced by VonVoigtlander
and Szmuszkovicz, the guandine derivative GNTI15 devel-
oped by Portoghese and co-workers, and the tetrahydroiso-
quinoline JDTic16,17 developed by Carroll and co-workers
(Figure 1). Herein, we report that comparatively simple
and synthetically accessible octahydroisoquinolone carbox-
amides of the general structure 1 represent a new class of
selective KOR ligands. This new chemotype is distinct from
most known smallmolecule KOR ligands in that the nitrogen
atoms present are neutral by their involvement in amide
bond resonance. Eight of the compounds reported here bind
to the KOR at concentrations <1 μM with no measurable
affinity for any other tested neurotransmitter receptor. Func-
tional studies reveal individual compounds of this chemo-
type to be full agonists of varying efficacy.
Recently, we reported an efficient synthesis of octahydro-
isoquinolone carboxylic acids utilizing a tandem Diels-
Alder/acylation sequence (Scheme1).18 Subsequent elaboration
of the carboxylic acids via carbodiimide coupling with a
selection of amines afforded an initial set of 72 octahydroiso-
quinolone carboxamides. The requisite amine-containing
dienes 2 are readily obtained18,19 bearing diverse R1 groups.
A tandem Diels-Alder/acylation reaction sequence between
these dienes and maleic anhydride 3 then affords the
carboxylic acid scaffolds 4 in good yields (68-80%). The
exclusive cis, cis relative configuration of the bicyclic frame-
work and pendant carboxylic acid group in the product 4 is
consistent with either a Diels-Alder reaction followed by an
intramolecular acylation or the inverse sequence.20 The acid
scaffolds 4 were further diversified by carbodiimide-mediated
couplingwith a selection of 12 commercially available amines to
afford the octahydroisoquinolone carboxamides 1. The nature
of the carboxylic acid and amine components utilized in the
construction of this initial library of octahydroisoquinolone
carboxamides is detailed in Figure 2. This sequence provides
anefficientandhigh-yielding route toapotentially vastcollection
of octahydroisoquinolone carboxamides, as demonstrated by
the synthesis of this initial 72 member compound set.
Our interest in the development of methods to enable the
synthesis of compound collections is partiallymotivated by a
curiosity in the biological profile of the final products of these
efforts. To this end, 50 library compounds were selected to
represent the diverse range of functional groups in the
collection and subsequently screened against 41 individual
G protein-coupled receptor (GPCR) assays using the re-
sources of the NIMH Psychoactive Drug Screening Program.
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Compounds were first screened at each GPCR target at
a constant concentration (10 μM) to identify active
compounds.21 Active compounds from initial binding
screens were selected for Ki determinations using radioli-
gand binding assays. A summary of the full results of the
secondary binding screen is depicted in heatmap format in
Figure 3. Most striking is a general selectivity trend of the
compounds for the KOR over not only the δ-opioid receptor
(DOR) and the μ-opioid receptor (MOR) but also against the
other GPCR targets screened. Several of the compounds
screened were found to be both highly selective for the
KOR and remarkably potent, most notably compounds 1l,
1n, 1y, 1aa, 1bb, and 1tt. Furthermore, the majority of the
compounds screened (35 out of 50) possesses experimen-
tally significant KOR binding (Ki < 10 μM), a remarkable hit
ratio from a set of compounds not synthesized with the
target assay in mind.
Isolated members of this compound set display binding
affinity for other GPCR targets. For example, compounds 1ss
and 1uu show potent binding affinity for the 5HT2B receptor
in addition to the KOR, the activation of which has been linked
to pulmonary hypertension.22 Compound 1mm displayed
selective, submicromolar affinity for the serotonin transporter,
and compound 1g was marginally selective for the DOR over
theKOR, providing promising entry points for future optimiza-
tion studies. At this time, however, we were most interested in
the KOR binding activity that appears to be generally char-
acteristic for this structural class of compounds.
The substituents on the 12 most potent compounds and
the numerical secondary binding data (Ki values) for the
DOR, KOR, and MOR receptor assays are shown in Table 1.
The data confirm high selectivity for the KOR over the DOR
and to a lesser extent the MOR for most of these examples,
except for one case where R2 = phenyl (entry 6). Com-
pounds where R2 = 4-chloro-3-trifluoromethylphenyl were
shown to be >10-fold selective for the KOR over the MOR/
DOR and to have the highest potency among the four sets of
amide derivatives examined (entries 9-12). While com-
pound 1xx containing a benzyl group in the R1 position
was highly potent, not all compounds containing benzyl at
R1 had similarly high affinity (cf. entries 1, 3, 6, and 12 in
Table 1).
Figure 1. Examples of known synthetic KOR ligands and the general isoquinolone amide structure.
Scheme 1. Synthesis of Octahydroisoquinolone Carboxamides
Figure 2. Components for the synthesis of the octahydroisoquino-
lone amide products 1.
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To further investigate the effect of the substituents on
potency, four additional compounds were synthesized ac-
cording to the protocol in Scheme 1 and screened for DOR,
KOR, andMOR binding in the primary and secondary assays
described above. These compounds, while not more potent
than compound 1{50} add a further three examples of
selective and potent KOR ligands in this structural class of
compounds (Table 2).
Compounds 1xx, 1yy, and 1zz were further evaluated in
KOR functional binding assays to determine whether they
behave as agonists or antagonists (Table 3). Thus, the con-
centration-dependent (ranging from 0.01 to 10000 nM)
inhibition of isoproterenol-stimulated cAMP accumulation
in hKOR-expressing HEK293T cells was measured for both
the test compounds and U-69,593 (a known KOR full
agonist). The three test compounds 1xx, 1yy, and 1zz were
all found to be full agonists (Emax = 100%) as compared to
U-69,593. The EC50 for compound 1zz is over 2 orders of
magnitude greater than the EC50 for the similar analogue
1yy; thus, given the two analogues' similar binding affinities,
the functional data suggest that the efficacy of this new
chemotype can be modulated by subtle structural modifica-
tions such as exchanging a triflouoromethyl substituent for a
methyl group.
In summary, we have discovered an attractive new
scaffold for KOR modulator discovery, with a number of
Figure 3. Activity of the isoquinonlone carboxamide compounds in secondary binding assays. Key: white, Ki > 10 μM/primary screen
missed; blue, Ki = 5-10 μM; green, Ki = 1-5 μM; yellow, Ki = 0.5-1 μM; red, Ki < 0.5 μM; and black, no data available. For the complete
binding data (Ki values) on these compounds, see the Supporting Information.
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representative analogues showing high potency and selec-
tivity toward the KOR. The synthetic methodology required
to procure these compounds is robust and provides an
efficient and straightforward route to analogues. The synth-
esis, screening, and evaluation of additional analogues are
ongoing and will be reported in due course.
SUPPORTING INFORMATION AVAILABLE Experimental
details and characterization data for all new compounds, structures,
and Ki values for each compound in all active assays shown in
Figure 3, purity assessment for all compounds, and assay protocols.
This material is available free of charge via the Internet at http://
pubs.acs.org.
AUTHOR INFORMATION
Corresponding Author: *To whom correspondence should be
addressed. Tel: 785-864-4496. E-mail: jaube@ku.edu.
Funding Sources: We thank the National Institute of General
Medical Sciences (GM-49093 and PO50-GM069663), the National
Institute of Mental Health's Psychoactive Drug Screening Program
[Contract #HHSN-271-2008-000025-C (NIMH-PDSP)], and RO1DA-
017204 for financial support.
ACKNOWLEDGMENT We are grateful to Benjamin Neuens-
wander for HR-MS and compound purification.
ABBREVIATIONS KOR, κ-opioid receptor; DOR, δ-opioid
receptor; MOR, μ-opioid receptor; GPCR, G protein-coupled
receptor.
REFERENCES
(1) McCurdy, C. R.; Prisinzano, T. E. Opioid receptor ligands. In
Burger's Medicinal Chemistry, Drug Discovery and Develop-
ment, 7th ed.; Abraham, D. J., Rotella, D. P., Eds.; John Wiley
& Sons: New York, NY, 2010.
(2) Aldrich, J. V.; McLaughlin, J. P. Peptide kappa opioid receptor
ligands: Potential for drug development. AAPS J. 2009, 11,
312–322.
(3) Metcalf, M. D.; Coop, A. Kappa opioid antagonists: Past
successes and future prospects. AAPS J. 2005, 7, E704–E722.
(4) Prisinzano, T. E.; Tidgewell, K.; Harding, W. W. k Opioids as
potential treatments for stimulant dependance. AAPS J.
2005, 7, E592–E599.
(5) Glick, S. D.; Maisonneuve, I. M.; Raucci, J.; Archer, S. Kappa-
opioid inhibition of morphine and cocaine self-administra-
tion. Brain Res. 1995, 681, 147–152.
(6) Reindl, J. D.; Rowan, K.; Carey, A. N.; Peng, X.; Neumeyer,
J. L.; McLaughlin, J. P. Antidepressant-like effects of the novel
kappa opioid antagonist MCL-144B in the forced-swim test.
Pharamcology 2008, 81, 229–235.
(7) Knoll, A. T.; Meloni, E. G.; Thomas, J. B.; Carroll, F. I.; Carlezon,
W. A., Jr. Anxiolytic-like effects of kappa-opioid receptor
antagonists in models of unlearned and learned fear in rats.
J. Pharmacol. Exp. Ther. 2007, 323, 838–845.
(8) Mague, S. D.; Pliakas, A. M.; Todtenkopf, M. S.; Thomasiewicz,
H. C.; Zhang, Y.; Stevens, W. C. J.; Jones, R. M.; Portoghese,
P. S.; Carlezon, W. A., Jr. Antidepressant-like effects of κ-opioid
receptor antagonists in the forced swim test in rats J. Pharma-
col. Exp. Ther. 2003, 305, 323–330.
(9) Millan, M. J. Kappa-opioid receptor-mediated antinocicep-
tion in the rat. 1. Comparative actions of mu-opioids and
Table 1. Selected Binding Data for Four Sets of Potent Isoquino-
lone Carboxamide Compounds
Ki (μM)
entry compound scaffold R1 DOR KOR MOR
1 1l 1a benzyl >10 0.30 >10
2 1n 1a cylcohexyl >10 0.17 >10
3 1y 1b benzyl >10 0.20 >10
4 1aa 1b cylcohexyl >10 0.16 >10
5 1bb 1b n-butyl >10 0.36 >10
6 1cc 1c benzyl 0.85 0.15 2.57
7 1ee 1c cylcohexyl >10 0.07 8.94
8 1gg 1c 3,4-dichloro-benzyl 1.11 0.26 2.70
9 1ss 1d cylcopropyl >10 0.49 >10
10 1tt 1d cylcohexyl >10 0.11 >10
11 1uu 1d n-butyl >10 0.19 2.22
12 1xx 1d benzyl >10 0.005 3.55
Table 2. Additional Isoquinolone Carboxamide Analogues and
Opioid Receptor Binding Profiles
Ki (μM)
compound R2 DOR KOR MOR
1yy 4-chloro-3- trifluoromethylphenyl >10 0.10 >10
1zz 4-chloro-3-methylphenyl >10 0.03 >10
1aaa 2,6-difluorophenyl >10 5.00 >10
1bbb 2,4-dichlorophenyl >10 0.29 >10
Table 3. KOR cAMP Reporter Assay Secondary Functional Bind-
ing Results





r 2010 American Chemical Society 193 DOI: 10.1021/ml100040t |ACS Med. Chem. Lett. 2010, 1, 189–193
pubs.acs.org/acsmedchemlett
kappa-opioids against noxious thermal, pressure and electri-
cal stimuli. J. Pharmacol. Exp. Ther. 1989, 251, 334–341.
(10) Roth, B. L.; Baner, K.; Westkaemper, R.; Siebert, D.; Rice,
K. C.; Steinberg, S.; Ernsberger, P.; Rothman, R. B. Salvinorin
A: A potent naturally occurring nonnitrogenous kappa
opioid selective sgonist. Proc. Natl. Acad. Sci. U.S.A. 2002,
99, 11934–11939.
(11) Kaczor, A.; Matosiuk, D. Non-peptide opioid receptor ligands;
Recent advances. Part I. Agonists. Curr. Med. Chem. 2002, 9,
1567–1589.
(12) Kaczor, A.; Matosiuk, D. Non-peptide opioid receptor ligands;
Recentadvances. Part II. Antagonists.Curr.Med. Chem.2002,9,
1591–1603.
(13) For a recently reported KOR agonist, see Kracht, D.; Rack, E.;
Schepmann, D.; Fr€ohlich, R.; W€unsch, B. Stereoselective
synthesis and structure-affinity relationships of bicyclic
receptor agonists. Org. Biomol. Chem. 2010, 8, 212–225.
(14) VonVoigtlander, P. F.; Szmuszkovicz, J. Benzeneacetamide
amines: Structurally novel non-μ opioids. J. Med. Chem.
1982, 25, 1125–1126.
(15) Jones, R. M.; Portoghese, P. S. 50-Guanidinonaltrindole, a
highly selective and potent κ-opioid receptor antagonist.
Eur. J. Pharmacol. 2000, 396, 49–52.
(16) Cueva, J. P.; Cai, T. B.; Mascarella, S. W.; Thomas, J. B.;
Navarro, H. A.; Carroll, F. I. Synthesis and in vitro opioid
receptor functional antagonismofmethyl-substituted analogues
of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-
dimethyl-1-piperidinyl]methyl}-2-methylpropyl]-1,2,3,4-tetra-
hydro-3-isoquinolinecarboxamide (JDTic). J. Med. Chem. 2009,
52, 7463–7472.
(17) Cai, T. B.; Zou, Z.; Thomas, J. B.; Brieaddy, L.; Navarro, H. A.;
Carroll, F. I. Synthesis and in vitro opioid receptor functional
antagonism of analogues of the selective kappa receptor
antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxy-
phenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-
1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic). J. Med.
Chem. 2008, 51, 1849–1860.
(18) Frankowski, K. J.; Hirt, E. E.; Zeng, Y.; Neuenswander, B.;
Fowler, D.; Schoenen, F.; Aube, J. Synthesis of N-alkyl-octahy-
droisoquinolin-1-one-8-carboxamide libraries using a tandem
Diels-Alder/acylation sequence. J. Comb. Chem.2007, 9, 1188–
1192.
(19) Plietker, B.; Seng, D.; Fr€ohlich, R.; Metz, P. High pressure
intramolecular Diels-Alder reactions of vinylsulfonates and
vinylsulfonamides. Tetrahedron 2000, 56, 873–879.
(20) For a more detailed discussion of these possible pathways,
see ref 18.
(21) Data were measured as the mean % inhibition (N = 4
determinations) for compounds tested at receptor subtypes.
Significant inhibition is considered >50%. For full experi-
mental details, see the Supporting Information.
(22) Launay, J.-M.; Herve, P.; Peoc'h, K.; Tournois, C; Callebert,
JNeigil, C. G.; Etienne, N.; Drouet, L.; Humbert,M.; Simonneau,
G.; Maroteaux., L. Function of the serotonin 5-hydroxytrypta-
mine 2B receptor in pulmonary hypertension. Nature Med.
2002, 8, 1129–1135.
